Skip to main content
SpringerLink
Log in

Cardiac Arrhythmias in Cancer Patients

  • Chapter
  • First Online:
Manual of Cardio-oncology

  • 695 Accesses

Abstract

Patients with cancer may have several kinds of arrhythmias either as an independent comorbidity or as a consequence of the cancer itself or of the antineoplastic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.

    Article  CAS  PubMed  Google Scholar 

  2. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.

    Article  CAS  PubMed  Google Scholar 

  3. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.

    Article  PubMed  Google Scholar 

  4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–42.

    Article  PubMed  Google Scholar 

  5. Driver JA, Djoussé L, Logroscino G, Gaziano JM, Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ. 2008;337:a2467.

    Article  PubMed  PubMed Central  Google Scholar 

  6. D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368–74.

    Article  PubMed  Google Scholar 

  7. Siu CW, Tung HM, Chu KW, Jim MH, Lau CP, Tse HF. Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer. Pacing ClinElectrophysiol. 2005;28 Suppl 1:S120–3.19.

    Article  Google Scholar 

  8. Bhave PD, Goldman LE, Vittinghoff E, Maselli J, Auerbach A. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major non cardiac surgery. Am Heart J. 2012;164:918–24.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundaro C. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med. 2008;3:227e231.

    Article  Google Scholar 

  10. Velagapudi P, Turagam MK, Kocheril AG. Atrial fibrillation in cancer patients: an underrecognized condition. South Med J. 2011;104:667–8.

    Article  PubMed  Google Scholar 

  11. Lainscak M, Dagres N, Filippatos GS, Anker SD, Kremastinos DT. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol. 2008;128:311–5.

    Article  PubMed  Google Scholar 

  12. Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon. 2005;51:150–7.

    Article  PubMed  Google Scholar 

  13. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J ClinOncol. 2005;23:2130–5.

    Article  CAS  Google Scholar 

  14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. For the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  15. Lee Y-J, Park J-k, Uhm J-S, Kim J-Y, Pak H-N, Lee M-H, Sung J-H, Joung B. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy International. J Cardiol. 2016;203:372–8.

    Google Scholar 

  16. Frendl G, Sodickson AC, Chung MK, et al.; American Association for Thoracic Surgery. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg. 2014;148(3):e153–93. Epub 2014 Jun 30. Review.

    Google Scholar 

  17. Hinterseer M, Becker A, Kaab S, Lang N, Nabauer M, Steinbeck G. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol. 2006;95:474–6.

    Article  CAS  PubMed  Google Scholar 

  18. Fahdi IE, Gaddam V, Saucedo JF, Kishan CV, Vyas K, Deneke MG, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93(8):1052–5.

    Article  CAS  PubMed  Google Scholar 

  19. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021–30.

    Article  CAS  PubMed  Google Scholar 

  20. Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273–9.

    Article  PubMed  Google Scholar 

  21. Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Mono. 1993;15:117–30.

    Google Scholar 

  22. Yavas O, Aytemır K, Celık I. The prevalence of silent arrhythmia in patients receiving cisplatin-based chemotherapy. Turkish J Cancer. 2008;38(1):12–5.

    Google Scholar 

  23. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol. 1990;29(8):1001–3.

    Article  CAS  PubMed  Google Scholar 

  24. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res ClinOncol. 2008;134(1):75–82.

    Article  CAS  Google Scholar 

  25. Oleksowicz L, Escott P, Leichman GC, Spangenthal E. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma. Am J ClinOncol. 2000;23:34–6.

    Article  CAS  Google Scholar 

  26. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  27. Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer. 1986;57(10):2061–9.

    Article  CAS  PubMed  Google Scholar 

  28. Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T, et al. Cardiac involvement in bone marrow transplantation:electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91–8.

    CAS  PubMed  Google Scholar 

  29. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24(6):352–61.

    Article  CAS  PubMed  Google Scholar 

  30. Haqqani HM, Morton JB, Kalman JM. Using the 12-lead ECG to localize the origin of atrial and ventricular tachycardias: part 2--ventricular tachycardia. J Cardiovasc Electrophysiol. 2009;20(7):825–32.

    Article  PubMed  Google Scholar 

  31. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295.

    Article  CAS  PubMed  Google Scholar 

  32. US FDA drug approval summary for vandetanib in medullary thyroid cancer. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf. Accessed 25 Apr, 2011.

  33. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoSOne. 2012;7, e30353.

    Article  CAS  Google Scholar 

  34. FDA-approved manufacturer's package insert for vandetanib. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525. Accessed 25 Jan 2013.

  35. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J ClinOncol. 2008;26:5204.

    Article  Google Scholar 

  36. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J ClinOncol. 2007;25:3362.

    Article  CAS  Google Scholar 

  37. Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009;15:7045.

    Article  CAS  PubMed  Google Scholar 

  38. Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67:751.

    Article  CAS  PubMed  Google Scholar 

  39. US Food and Drug Administration (FDA)-approved manufacturer's package insert. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=807f988e-117b-4497-934d-73aa78baac71. Accessed 03 Jan 2013.

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCS, Naples, Italy

    Nicola Maurea, Iris Parrini & Irma Bisceglia

Authors
  1. Nicola Maurea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris Parrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irma Bisceglia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iris Parrini .

Editor information

Editors and Affiliations

  1. Cardiology Unit, IRCCS CRO-National Cancer Institute, Aviano (PN), Italy

    Chiara Lestuzzi

  2. Cardiology Unit, National Cancer Institute “Giovanni Paolo II”, Bari, Italy

    Stefano Oliva

  3. Medical Oncology Unit, Ospedale San Vincenzo, Taormina, Italy

    Francesco Ferraù

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Maurea, N., Parrini, I., Bisceglia, I. (2017). Cardiac Arrhythmias in Cancer Patients. In: Lestuzzi, C., Oliva, S., Ferraù, F. (eds) Manual of Cardio-oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-40236-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40236-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40234-5

  • Online ISBN: 978-3-319-40236-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation